Sign in to view content

Masked Safety Data from ZETA-1, an Ongoing 24-Week Phase 2 Clinical Trial of APX3330, an Oral Therapeutic Being Developed for the Treatment of Diabetic Retinopathy

Michael J Allingham, MD, PhD

Video
Published 2022

Related

Real-World Impact of Early Treatment With Intravitreal Dexamethasone Implant in DME in US Clinical Practice: Outcomes From the Vestrum Database
Roger A. Goldberg, MD, MBA
On Demand Cases, Courses, and Papers
2021
Patients Ultra-Responsive to Ranibizumab (RBZ): Rates of Great Than or Equal to 4-Step Improvement in Diabetic Retinopathy Severity in DRCR.net Protocol S
Allen Chiang, MD, FASRS
Annual Meeting Talks
2019
Diabetic Retinopathy 1 Symposium
Annual Meeting Talks
2020

Category: Diabetic Retinopathy

See more